A Phase 1 study of ACK1 inhibitor (R)-9bMS in prostate cancer
Recruiting Phase 1 NCT06705686
Study Description
A Phase 1 study to evaluate the safety and effectiveness of a new drug, (R)-9bMS, in patients with advanced prostate cancer
Study Details
- Registry ID:
- NCT06705686
- Conditions:
- Metastatic Castration-resistant Prostate Cancer (CRPC), Metastatic Castration-resistant Prostate Carcinoma
- Phase:
- Phase 1
- Target Enrollment:
- 40 participants
- Start Date:
- Healthy Volunteers:
- No
Study Locations (1 site)
-
University of Wisconsin Carbone Cancer Center (UWCCC) - Cancer Connect
Madison, Wisconsin, United States
Interested in Participating?
Check your eligibility and learn more about this study on TrialScreen.